Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1326912 (tumorigenesis)
 57,481 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Induction of skin tumors by 7,12-dimethylbenz(a)anthracene (DMBA) in the presence of its metabolites-7-hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-12-MBA) and 7,12-dihydroxymethylbenz(a)anthracene (7,12-diOHMBA) has been studied in mice. The skin of mice was treated repeatedly with benzene or acetone solutions of DMBA (22 mug in two droplets) or with the same amount of DMBA solution together with one of the above mentioned metabolites (the molecular ratio 1 : 1 or 1 : 0.5). Neither of the metabolites affected the carcinogenic activity of DMBA under the given conditions. 7,8-benzoflavone, an inhibitior of the DMBA metabolism, strongly suppressed DMBA tumorigenesis under the same experimental conditions. Whereas the effect of benz(a)-anthracene, an inducer of aryl hydrocarbon hydroxylase activity, was less pronounced.
 ...
PMID:[Effect of 7,12-dimethylbenz(alpha)anthracene metabolites on its capacity to induce skin tumors in mice]. 81 Sep 68

Nitrobenzo[a]pyrenes (NBaPs) are ubiquitous environmental pollutants that produce mutations in Salmonella typhimurium and Chinese hamster ovary cells. In this study, 1-, 3-, and 6-NBaP induced amplification of SV40 DNA sequences in an SV40-transformed Chinese hamster embryo cell line which is sensitive to DNA amplification by various known carcinogens. Of the three isomers, 3-NBaP produced the highest level of gene amplification, which was 4.8 relative to untreated controls at a dose of 5 micrograms/ml. Considering the relationship between gene amplification and tumorigenesis, it seems prudent to carry out a more exhaustive analysis of the carcinogenic potential of these agents.
Environ Mol Mutagen 1992
PMID:Nitrobenzo[a]pyrene-induced DNA amplification in SV40-transformed Chinese hamster embryo cells. 131 74

The relationship between chemically induced patterns of tumorigenesis in rodents and of in vitro genetic toxicity was evaluated for 73 substances. tumorigenicity patterns were defined according to sex and species effects, the induction of common or uncommon tumors, and benign or malignant tumors. These results and the genetic toxicity results derived from the testing of chemicals under code were compared. Chemicals that induced tumors in both sexes of both rodent species (trans-sex/species carcinogens) were divided into those that showed multiple responses in genetic toxicity assays and those that showed little or no response. Some of the nongenotoxic trans-sex/species carcinogens exhibit properties that do not necessarily fit classification as only tumor promoters and may involve some other mode(s) of action. Those chemicals showing tumorigenicity in only one of the four groups exposed (uni-sex/species carcinogens) generally showed little or no response in genetic toxicity assays. Uni-sex/species carcinogens may be difficult to identify by in vitro assays because of their high tissue specificity. Chemicals that are tumorigenic in both sexes of both species are logically more likely to be tumorigenic in a third species than are those that are tumorigenic in only one sex of the exposed species. Therefore, while positive genetic toxicity test results are not predictive of all carcinogens, a consistent positive response among the multiple endpoints in these assays is more likely to identify chemicals with the potential for trans-sex/species carcinogenesis. Such trans-sex/species carcinogens may have the most direct implication for human health effects.
Environ Mutagen 1986
PMID:Comparison of multiple parameters of rodent carcinogenicity and in vitro genetic toxicity. 369 43

A single dose (36 rad) of X rays was given to mouse embryos and neonates that were then treated with urethane at 21 days of age. Although in utero X-radiation to mice was not tumorigenic, it significantly increased lung tumor susceptibility to a postnatally-given carcinogen, urethane. X-ray induction of persistent hypersensitivity to lung tumorigenesis was apparent at all stages during days 0 to 14 of gestation (except on day 6), but was not observed at late fetal and neonatal stages.
Environ Mutagen 1984
PMID:Induction of persistent hypersensitivity to lung tumorigenesis by in utero X-radiation in mice. 669 99

Recent reports suggest that ascorbic acid (vitamin C) inhibits tumorigenesis as well as exerts a protective effect against mutagenesis in vitro; however, there is no information on its ability to affect gene mutations induced in vivo. In this study, we have investigated the antimutagenic effects of ascorbic acid on the frequency of 6-thioguanine-resistant (6-TGr) T-lymphocytes produced in Fischer 344 rats dosed with the direct-acting alkylating agent, N-ethyl-N-nitrosourea (ENU). The frequency of 6-TGr T-lymphocytes from the spleen measured five weeks after ENU treatment indicated that ENU produced a substantial mutagenic response. Pretreatment and/or post-treatment of rats with ascorbic acid administered in the drinking water appeared to inhibit the response, but the inhibition was statistically significant only when data from the various dosing schedules were pooled. In addition, there was no clear dose-dependency to the inhibitory effect of ascorbic acid. To further evaluate the time effects of the vitamin supplement on ENU mutagenicity, rats were exposed to the mutagen together with ascorbic acid, which was given continuously for the entire duration of the experiment. At specific times after ENU treatment, the frequency of 6-TGr T-cells was determined in lymphocytes isolated from the spleen and the thymus. Time-dependent increases in the frequency of 6-TGr T-cells were observed with ENU treatment; ascorbic acid significantly reduced the ENU-mediated mutagenic responses, most dramatically in the spleen at weeks 6 and 8 (P < 0.0001), and to a lesser extent in the thymus (P < 0.01 at week 6 and P < 0.006 at week 8). Our data suggest that ascorbic acid intake affects the in vivo mutagenicity of ENU, a direct-acting mutagen/carcinogen, and that the reported inhibitory effects of the antioxidant on carcinogenesis may be partially mediated by its effects on mutagenesis. Although it is difficult to extrapolate from rodent studies to humans, the results presented suggest an explanation for epidemiological data that link vitamin C ingestion with decreased cancer risk.
Environ Mol Mutagen 1994
PMID:Ascorbic acid (vitamin C) modulates the mutagenic effects produced by an alkylating agent in vivo. 795 25

The modulatory influence of arecanut, a masticatory in several human populations, on the levels of biotransformation system enzymes in mouse liver has been studied. Swiss albino mice of either sex (4 weeks old) were fed on diets containing 0.25%, 0.5%, or 1% arecanut (w/w) for 5 weeks. In addition, a group of mice received a 1% arecanut diet for 36 weeks. The findings revealed a significant increase in hepatic levels of cytochrome b5, cytochrome P-450, malondialdehyde (MDA), and glutathione S-transferase (GST). The hepatic -SH content was depressed by 0.5% and 1% arecanut diets. Long-term feeding of a 1% arecanut diet elicited changes similar to those seen following treatment for 5 weeks. Arecanut-modulated profiles of biotransformation enzymes and antioxidant levels are suggestive of its influence in the process of carcinogenesis induced by bioactivated electrophilic species of potential chemical carcinogens among habitual arecanut chewers. Arecanut was also tested for its potency either to induce or to alter 7,12-dimethylbenz[a]anthracene (DMBA)-induced papillomagenesis in the skin of the mouse. Animals put on a 1% arecanut diet and treated with a standard two-stage protocol for tumor induction developed a 5.41 tumor burden (control value: 5.76) along with 100% incidence of mice bearing papillomas (control value: 94.4%), thus signifying that dietary intake of 1% arecanut for 18 weeks could not induce/alter the mouse skin tumorigenesis pattern.
Teratog Carcinog Mutagen 1995
PMID:Modulatory influence of arecanut on the mouse hepatic xenobiotic detoxication system and skin papillomagenesis. 858 85

We describe an in vivo mutagenesis model that utilizes reverse mutation and forward mutation at the endogenous Aprt locus. Reverse mutation provides an in situ method for detecting environments or agents that cause point mutations. Forward mutation detects large chromosomal events, including mitotic recombination, chromosome loss, and large multilocus deletion, all of which can lead to loss of heterozygosity. Detection of reverse mutation in vivo is based on the differential capacity of Aprt and Aprt cells to sequester radiolabeled adenine by catalyzing its conversion to adenosine monophosphate with subsequent incorporation into nucleic acids. Cells lacking APRT activity cannot accumulate exogenously administered, tagged adenine, whereas Aprt+ cells can and will thereby become marked. Thus, genetically modified mice with mutant but revertible Aprt alleles should be a useful vehicle for in situ detection of mutagenic activity in the whole animal. the feasibility of this model has been illustrated, first, by showing that APRT-deficient mice are viable and, second, by demonstrating that the minority of Aprt+ cells within a chimeric tumor growing in an Aprt+ mouse can be selectively labeled following IP injection of [14C]-adenine and can be identified by autoradiography. Forward mutation, detected by growth in selective medium of primary cells derived from Aprt+/- heterozygous mice, provides on independent estimate of in vivo mutation frequency. The frequency with which Aprt colonies arise provides a measure of the frequency of Aprt(-)-negative cells in the tissue at that point in time. Culture of skin fibroblasts in 2,6-diaminopurine (DAP) produced Aprt+ colonies with a frequency of about 10(-4). This frequency is similar to that found for human T lymphocytes from individuals heterozygous at the Aprt locus. In both cases, the majority of mutagenic events involved allele loss. Polymerase chain reaction with linked polymorphic microsatellites on mouse chromosome 8 demonstrated that allele loss was mediated mostly by mitotic recombination, as was the case for human T lymphocytes. The high frequency of mitotic recombination and allele loss at a neutral locus has significant implications for the process of tumorigenesis and argues that spontaneous or induced mitotic recombination may play a causal role in the progression to cancer.
Environ Mol Mutagen 1996
PMID:APRT: a versatile in vivo resident reporter of local mutation and loss of heterozygosity. 899 Oct 80

Many experimental studies for anticarcinogenic activity of green tea (Camellia sinensis) and tea-derived polyphenols have been carried out. However, the anticarcinogenic activity of the nonpolyphenolic fraction of green tea has been poorly elucidated. To study this problem, the effect of the nonpolyphenolic fraction of green tea leaves was analyzed using in vitro and in vivo experiments associated with tumor initiation and promotion as follows: 1) The nonpolyphenolic fraction caused a strong suppressive effect on umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002) induced by genotoxic substances such as 2-amino-6-methyldipirido[1,2-a:3',2'-d]imidazole (Glu-P-1) and 2-aminoanthracene (2-AA) in the presence of a hepatic metabolizing enzyme mixture. 2) The same fraction showed a dose-dependent inhibition of ornithine decarboxylase (ODC) in BALB/c 3T3 fibroblasts induced by a tumor promotor, 12-O-tetradecanoylphorbol-13-acetate (TPA). 3) The same fraction also exhibited a significant suppression against mouse skin tumorigenesis induced by 7,12-dimethylbenz[a]anthracene (DMBA) (initiator) and TPA (promotor) through inhibition at both stages of tumor initiation and promotion. These results suggest that the nonpolyphenolic fraction of green tea has a potent suppressing activity against carcinogenesis associated with tumor initiation and promotion.
Teratog Carcinog Mutagen
PMID:Potent suppressive activity of nonpolyphenolic fraction of green tea (Camellia sinensis) against genotoxin-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002), tumor promotor-dependent ornithine decarboxylase induction of BALB/c 3T3 fibroblast cells, and chemically induced mouse skin tumorigenesis. 948 39

The induction and nature of mutations in the lacI transgene were evaluated in multiple tissues after exposure of adult male B6C3F1 lacI transgenic mice to cyclophosphamide (CP). Mice were given a single i.p. injection of 25 mg CP/kg, 100 mg CP/kg, or vehicle (PBS) and then necropsied 6 weeks after treatment to allow DNA extraction and lacI mutant recovery. Tissues evaluated included target tissues for tumorigenesis (lung, urinary bladder) and sites not susceptible to tumor formation in B6C3F1 mice (kidney, bone marrow, splenic T-lymphocytes). After exposure to the high dose of CP, a significant increase in the mutant frequency (Mf) was detected in the lungs and urinary bladders, compared to the respective tissues from vehicle-treated controls. In contrast, the Mfs in kidney, bone marrow, and splenic T cells from CP-treated mice were not significantly different from controls. The spectra of mutations in lacI from lung and urinary bladder were significantly changed after high-dose CP treatment, with a significant increase in the frequency of A. T --> T. A transversions found in both tissues and a significantly elevated frequency of deletions in the lungs. Conversely, in vehicle-treated mice, the two predominant classes of lacI mutations recovered in lung and urinary bladder were G. C --> A. T transitions at CpG sites and G. C --> T. A transversions. These CP exposures were also genotoxic as measured by the significant induction of micronuclei in peripheral blood 48 hr after exposure. These data indicate that under these study conditions, CP-induced mutations are detectable in the lacI transgene in the target tissues, but not in nontarget tissues for CP-induced cancer. With the lacI assay it is possible to study mutagenicity in a variety of critical tissues to provide mechanistic information related to genotoxicity and carcinogenicity in vivo.
Environ Mol Mutagen 1999
PMID:Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. 1052 40

Accumulation of genetic damage in long-lived cell populations with proliferative capacity is implicated in tumorigenesis. Hematopoietic stem cells (hsc) maintain lifetime hematopoiesis, and recent studies demonstrate that hsc in leukemic patients are cytogenetically aberrant. We postulated that exposure to agents associated with increased leukemia risk would induce genomic changes in cells in the hsc compartment. Aneusomy involving chromosomes 2 and 11 in sorted hsc (Lin(-)c-kit(+)Sca-1(+)) and maturing lymphoid and myeloid cells from mice that received topical doses of benzene (bz) or trichloroethylene (TCE) was quantified using fluorescence in situ hybridization. Six days after bz or TCE exposure, aneuploid cells in the hsc compartment increase four- to eightfold in a dose- and schedule-independent manner. Aneuploid lymphoid and myeloid cells from bz- and TCE-treated mice approximate controls, except after repeated benzene exposures. Aneuploid cells are more frequent in the hsc compartment than in mature hematopoietic subpopulations. Hematotoxicity was also quantified in bz- and TCE-exposed hematopoietic subpopulations using two colony-forming assays: CFU-GM (colony-forming units/granulocyte-macrophage progenitors) and CAFC (cobblestone area-forming cells). Data indicate that bz is transiently cytotoxic (< or =1 week) to hsc subpopulations, and induces more persistent toxicity (>2 weeks) in maturing, committed progenitor subpopulations. TCE is not hematotoxic at the doses applied. In conclusion, we provide direct evidence for induction of aneuploidy in cells in the hsc compartment by topical exposure to bz and TCE. Disruption of genomic integrity and/or toxicity in hsc subpopulations may be one step in leukemic progression.
Environ Mol Mutagen 2001
PMID:Dermal benzene and trichloroethylene induce aneuploidy in immature hematopoietic subpopulations in vivo. 1131 36


1 2 3 4 5 Next >>